Bacteria Patents (Class 530/825)
-
Patent number: 6987173Abstract: A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies with an aqueous alcohol solution at an alkaline pH to solubilize said protein; and (b) bringing the solubilized protein into contact with a mild oxidizing agent to refold and form intramolecular disulfide bonds between cysteine residues of said protein.Type: GrantFiled: January 12, 2001Date of Patent: January 17, 2006Assignee: LG Chemical LimitedInventors: Yong-Jun Lee, Hong-Kyun Lee, Kyuboem Han
-
Patent number: 6974700Abstract: A kit and method of predicting a refractory response in a subject diagnosed as having periodontal disease by measuring serum concentrations of actinomyces antibodies, streptococcal antibodies and lysine decarboxylase antibodies and using the measurement along with other subject information in a set of derived equations.Type: GrantFiled: June 6, 2003Date of Patent: December 13, 2005Inventor: Martin Levine
-
Patent number: 6951653Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: May 30, 2001Date of Patent: October 4, 2005Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 6933365Abstract: A gene coding for a mutant tyrosine repressor having increased positive regulatory activity for expression of the tyrosine phenol lyase gene compared with a tyrosine repressor not having mutation is obtained by introducing a mutation into a tyrosine repressor gene of Erwinia herbicola, introducing the gene into which the mutation is introduced into Escherichia coli expressing a lactose operon under the control of a promoter and enhancer of the tyrosine phenol lyase gene derived from Erwinia herbicola, and selecting a transformed strain having increased ?-galactosidase activity.Type: GrantFiled: March 1, 2001Date of Patent: August 23, 2005Assignee: Ajinomoto Co., Inc.Inventors: Hidehiko Kumagai, Hideyuki Suzuki, Takane Katayama
-
Patent number: 6916665Abstract: Provided are pore-subunit polypeptides covalently linked to one or more sensing moieties, and uses of these modified polypeptides to detect and/or measure analytes or physical characteristics within a given sample.Type: GrantFiled: February 12, 2001Date of Patent: July 12, 2005Assignee: The Texas A&M University SystemInventors: Hagan P. Bayley, Stefan G. Howorka, Liviu Movileanu
-
Patent number: 6903184Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.Type: GrantFiled: July 10, 2000Date of Patent: June 7, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
-
Patent number: 6887980Abstract: The invention relates to novel pathogenic OrfF and OrfF? polypeptides derived from Xanthomonas campestris pv. campstris, the nucleic acid molecules encoding the polypeptides and the uses of the same for detecting or preventing a black-rot disease of a crucifer plant, making organic fertilizer or composting and being a biofilter for degradation of organic compounds.Type: GrantFiled: August 30, 2002Date of Patent: May 3, 2005Assignee: National Chung Hsing UniversityInventors: Jiann-Hwa Chen, Pei-Tseng Lee, Yin Liu
-
Patent number: 6887984Abstract: The invention relates to a process for preparing an anti-freeze peptide and to the peptides obtained from bacteria from an aqueous low-temperature environment, such as Marinomonas protea and a Pseudomonas species. These anti-freeze peptides can suitably be incorporated in frozen food products such as frozen vegetables and frozen confectionery such as ice-cream.Type: GrantFiled: December 15, 2000Date of Patent: May 3, 2005Assignee: Good Humor-Breyers Ice Cream, a division of Conopco, Inc.Inventors: Mark John Berry, Allen Griffiths, Philip John Hill, Johanna Laybourne-Parry, Sarah Victoria Mills
-
Patent number: 6887480Abstract: The present invention relates to novel immunogenic polypeptides, and fragments thereof, and vaccines for the prevention and treatment of pneumococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as vaccines containing said polypeptides and methods of disease prevention.Type: GrantFiled: June 9, 2000Date of Patent: May 3, 2005Assignee: MedImmune, Inc.Inventors: John E. Adamou, Gil H. Choi
-
Patent number: 6866855Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.Type: GrantFiled: June 11, 2001Date of Patent: March 15, 2005Assignee: University of SaskatchewanInventors: Alexandra J. Bolton, Jose Perez-Casal, Michael Fontaine, Andrew A. Potter
-
Patent number: 6861507Abstract: Methods of screening for vaccine candidates, vaccines against pathogenic neisscria and intermediaries for such vaccines have been developed. Two vaccine candidates TspA and TspB have been identified and characterised which either alone or in conjunction with the vaccines provide for treatment against pathogenic neisserias in particular Neisseria meningitidis and/or Neisseria gonorrhoea.Type: GrantFiled: July 9, 1999Date of Patent: March 1, 2005Assignee: University of NottinghamInventors: Dlawer Ala'Aldeen, Ian Todd
-
Patent number: 6855321Abstract: The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines arm particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: April 27, 1999Date of Patent: February 15, 2005Assignee: Chiron S.r.l.Inventors: Rino Rappuoli, Guido Grandi
-
Patent number: 6849715Abstract: A method of treating a disorder characterized by an activating mutation in a Ras proto-oncogene, comprising contacting cells of a patient suffering from the disorder with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivation of Ras by glucosylation of Ras' threonine 35 in said cell. The protein preferably is an immunotoxin that contains as a toxic domain the catalytic domain of toxin LT.Type: GrantFiled: July 31, 1998Date of Patent: February 1, 2005Assignee: Zentaris AGInventors: Christoph Von Eichel-Streiber, Patrice Boquet, Monica Thelestam
-
Patent number: 6846804Abstract: A sublancin peptide variant having a Gly-His peptide sequence fused to the C-terminal end of the mature sublancin peptide provides an affinity tag facilitating increased purification of the peptide variant from sample preparations without affecting the intracellular processing of the sublancin peptide variant, expression by a host cell or its biological activity in secreted form. This sublancin variant has specific inhibitory activity for spore outgrowth as for the native sublancin peptide. Production of the sublancin peptide variant on an industrial scale is set forth as are methods of decontaminating spore-infected areas. Methods for generating the peptide variant gene, plasmid and transformant are also described.Type: GrantFiled: June 29, 2001Date of Patent: January 25, 2005Assignee: University of Maryland, College Park Office of Technology CommercializationInventor: J. Norman Hansen
-
Patent number: 6833355Abstract: The use of protein H, and fragments or derivatives thereof, as cytostatic agents, especially in the treatment of diseases involving undesired cell proliferation.Type: GrantFiled: May 11, 2000Date of Patent: December 21, 2004Assignee: Hansa Medical ABInventors: Lars H. Björck, Inga-Maria Frick, Tomas Borje Leandersson, Eugen Jan Karol Axcrona
-
Patent number: 6833134Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.Type: GrantFiled: April 26, 2002Date of Patent: December 21, 2004Assignee: University of SaskacthewanInventors: Alexandra J. Bolton, Jose Perez-Casal, Michael Fontaine, Andrew A. Potter
-
Patent number: 6822071Abstract: Chlamydia pneumoniae polypeptides are provided. The C. pneumoniae polypeptides can be used to prepare pharmaceutical compositions for the treatment or prevention of disease. In addition, the proteins can be used in methods for the diagnosis of C. pneumoniae infection.Type: GrantFiled: November 11, 1999Date of Patent: November 23, 2004Assignee: The Regents of the University of CaliforniaInventors: Richard S. Stephens, Wayne Mitchell, Sue S. Kalman, Ronald Davis
-
Patent number: 6814970Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.Type: GrantFiled: October 9, 2001Date of Patent: November 9, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Ariadna Sadziene, Alan G. Barbour
-
Patent number: 6808902Abstract: The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The pharmacologically active compound can be an antibody or a fusion molecule comprising a pharmacologically active domain and an Fc domain. The preferred copper (II) halide is CuCl2. The preferred concentration thereof is at least about 10 mM for fusion molecules prepared in E. coli; at least about 30 mM for fusion molecules prepared in CHO cells. The process can be employed with any number of pharmacologically active domains. Preferred pharmacologically active domains include OPG proteins, leptin proteins, soluble portions of TNF receptors (e.g., wherein the fusion molecule is etanercept), IL-1ra proteins, and TPO-mimetic peptides.Type: GrantFiled: November 9, 2000Date of Patent: October 26, 2004Assignee: Amgen Inc.Inventors: Michael J. Treuheit, Sheila R. O'Conner, Andrew A. Kosky
-
Patent number: 6800734Abstract: Four antigenic preparations are provided, each of which contains a different protein from Leptospira which can be used immunologically in vaccines for leptospirosis caused by this organism. Also provided in the invention are polynucleotides encoding these four proteins and antibodies which bind the proteins for use in the diagnosis of leptospirosis.Type: GrantFiled: September 25, 2002Date of Patent: October 5, 2004Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Eric A. Utt, Michael Stephen Willy, Don A. Dearwester
-
Patent number: 6780420Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: October 5, 2000Date of Patent: August 24, 2004Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Nguyen Ngoc
-
Patent number: 6764686Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.Type: GrantFiled: July 21, 1998Date of Patent: July 20, 2004Assignee: Baxter International Inc.Inventors: Conceicao Minetti, Francis Michon, Jeffrey K. Pullen, Mary Ellen Polvino-Bodnar, Shu-Mei Liang, Joseph Y. Tai
-
Patent number: 6759205Abstract: A sublancin peptide variant (lantibody) having a spacer region and a subtilin leader peptide fused to the C-terminal end of the mature sublancin peptide provide an anchoring means for inserting and retaining the lantibody in a host cell wall without affecting the intracellular processing of the lantibody, host cell expression of the molecule on the cell surface or the biological activity of the mature sublancin peptide in extracellular, cell-wall-bound form. Target molecules that bind to the lantibody and methods of engineering a peptide variant gene, plasmid and a host cell transformant are described as are methods of using a lantibody to identify new target molecules.Type: GrantFiled: June 29, 2001Date of Patent: July 6, 2004Assignee: University of MarylandInventor: J. Norman Hansen
-
Patent number: 6759516Abstract: The present invention relates to method of identifying gene sequences of potential vaccine antigens. Also included are gene sequences and the polypeptides encoded by the gene sequences as well as the use of such sequences to induce a protective immune response in animals. Particularly, the invention relates to identifying potential antigen gene sequences of Mycoplasma, preferably Mycoplasma hyopneumoniae. In one aspect of the present invention there is provided a method of identifying expression proteins translated from a nucleotide sequence in an expression vector, said method comprising the use of a marker co-expressed with a protein translated from the nucleotide sequence. In a further aspect of the present invention there is provided a method of identifying a therapeutic antigenic gene sequence encoding a therapeutic antigenic protein of a disease, from a sample of nucleotide sequences. Preferably the marker is a polyHis tag.Type: GrantFiled: May 21, 2001Date of Patent: July 6, 2004Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Robert John Moore, Timothy James Doran
-
Patent number: 6747129Abstract: The present invention is directed to a protein isolated from S. aureus that is the target of RAP, called TRAP, which is characterized by a molecular weight of about 21 KDa, is capable of being phosphorylated by RAP, and comprises an amino acid sequence of SEQ ID NO:2. In addition, the present invention is directed towards an antibody immunoreactive with TRAP that is preferably a monoclonal antibody or a humanized antibody but may be a polyclonal antibody. The invention provides a method of treating S. aureus infection by administering such a TRAP-inhibiting agent. The invention also features methods for identifying compounds that inhibit TRAP activity and/or inhibit TRAP-RAP interaction.Type: GrantFiled: September 10, 1999Date of Patent: June 8, 2004Assignee: The Regents of the University of CaliforniaInventors: Naomi Balaban, Tzipora Goldkorn
-
Patent number: 6733758Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: April 1, 1999Date of Patent: May 11, 2004Inventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Patent number: 6716433Abstract: The present invention provides immunogenic synthetic fusion polypeptide which stimulates an immune response against a selected pathogen, comprising at least two immunogenic polypeptides from a Group A streptococci of at least 10 amino acids in length which are capable of stimulating an immune response against Group A strepococci, and a peptide C terminal to the immunogenic polypeptide which protects the immunogenicity of the immunogenic portion, wherein the C-terminal peptide is not required to stimulate an immune response against Group A streptococci.Type: GrantFiled: September 10, 1998Date of Patent: April 6, 2004Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Patent number: 6706269Abstract: The invention provides BASB031 polypeptides and polynucleotides encoding BASB031 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: May 12, 2000Date of Patent: March 16, 2004Assignee: SmithKline Beecham Biologicals s.a.Inventors: Jean-Louis Ruelle, Carlota Vinals Y De Bassols
-
Patent number: 6689595Abstract: An unliganded form of Staphylococcus aureus thymidylate kinase (S. aureus TMK) has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus TMK activity.Type: GrantFiled: August 4, 2000Date of Patent: February 10, 2004Assignee: Pharmacia & Upjohn CompanyInventor: Timothy E. Benson
-
Patent number: 6685945Abstract: An antigenic preparation is provided which contains a 31 Kd outer membrane protein from Leptospira which can be used immunologically as a vaccine for leptospirosis caused by this organism.Type: GrantFiled: August 19, 1997Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: David A. Haake, David R. Blanco, Cheryl I. Champion, Michael A. Lovett, James N. Miller
-
Patent number: 6682744Abstract: Strains of Lactobacilli having the ability to reduce or block pro-inflammatory cytokines and also to induce anti-inflammatory cytokines are disclosed. These strains may be used to prepare therapeutic agents that reduce inflammation. Lactobacillus secreted proteins, carbohydrates and lipids are also disclosed. The Lactobacillus secretions, which block translocation of bacterial agents such as Gram (−) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of inflammation caused by bacterial translocation and injury and in treating gastrointestinal dysfunctions.Type: GrantFiled: August 9, 2000Date of Patent: January 27, 2004Assignee: University of MarylandInventor: Pinaki Panigrahi
-
Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V
Patent number: 6638515Abstract: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using protein V specific for IgG1 and/or IgG3. In one aspect of the invention, protein V blocks the binding of IgG1 and/or IgG3 to the Fc&ggr;RIII receptor, which inactivates the receptor, and destroys cellular forms containing the receptor.Type: GrantFiled: March 8, 2001Date of Patent: October 28, 2003Inventor: Walter Schubert -
Patent number: 6623737Abstract: The invention is related to antibodies, particularly monoclonal antibodies, which recognize particularly epitopes of the intimin protein of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of detecting such E. coli by use of these antibodies, and kits containing these antibodies for diagnosis.Type: GrantFiled: April 2, 1998Date of Patent: September 23, 2003Assignee: Imperial College of Science, Technology & MedicineInventors: Gordon Dougan, Gad Frankel
-
Publication number: 20030175293Abstract: The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.Type: ApplicationFiled: April 9, 2001Publication date: September 18, 2003Inventors: H. Robert Masure, Carsten I. Rosenow, Elaine Tuomanen, Theresa M. Wizemann
-
OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
Patent number: 6610306Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: November 26, 2001Date of Patent: August 26, 2003Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning -
Patent number: 6605287Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: GrantFiled: August 28, 1998Date of Patent: August 12, 2003Assignee: Board of Supervisors of Louisiana State University & Agricultural and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
-
Patent number: 6592872Abstract: The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.Type: GrantFiled: September 15, 1997Date of Patent: July 15, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kurt Klimpel, Theresa J. Goletz, Naveen Arora, Stephen H. Leppla, Jay A. Berzofsky
-
Patent number: 6573241Abstract: In a method of manufacturing a therapeutic agent to be administered intramuscularly for suppressing snoring noises a high-purity Clostridium toxin BoNT/A or TeNT or at least one of a high-purity Clostridium toxin BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F and BoNT/G is added to a carrier. In an alternative, one or more hybrid proteins as a Clostridium toxin, having a light subunit of a Clostridium toxin of the following group and a heavy subunit of a different Clostridium toxin of the same following group, which group contains BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G and TeNT, are added to a carrier. According to another alternative, a complex, containing a Clostridium toxin or a hybrid protein, and further containing one or more therapeutically well-tolerated hemagglutinins and/or pharmaceutically well-tolerated non-toxic proteins, is added to a carrier. The carrier can be an aqueous solution, a saline solution, or liposomes.Type: GrantFiled: June 8, 2001Date of Patent: June 3, 2003Assignee: BioteCon Gesellschaft für bio-technologische Entwicklung und Consulting GmbHInventors: Hans Bigalke, Jürgen Frevert
-
Publication number: 20030099663Abstract: The inventions discloses a pharmaceutical composition comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.Type: ApplicationFiled: April 1, 2002Publication date: May 29, 2003Applicant: Cistem Biotechnologies GMBHInventors: Julia-Kristina Fleitmann, Frank Mattner, Michael Buschle, Jack Melling
-
Patent number: 6548070Abstract: Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.Type: GrantFiled: July 7, 2000Date of Patent: April 15, 2003Assignee: Aventis Pasteur LimitedInventors: Bruno Flesselles, Michel H. Klein
-
Patent number: 6541453Abstract: Novel peptide derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing then are useful in treating MHC class II dependent T-cell method autoimmune or inflammatory diseases, such as rheumatoid arthritis.Type: GrantFiled: May 26, 1999Date of Patent: April 1, 2003Assignee: Syngenta LimitedInventors: Keith Oldham, Philip Neil Edwards, Richard William Arthur Luke, Ronald Cotton
-
Patent number: 6541007Abstract: A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS. 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO:3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA strains PAK and PAO.Type: GrantFiled: June 30, 1999Date of Patent: April 1, 2003Assignee: The Governors of the University of AlbertaInventors: Robert S. Hodges, Randall T. Irvin, Paul J. Cachia
-
Patent number: 6534628Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.Type: GrantFiled: May 21, 1998Date of Patent: March 18, 2003Assignee: Biovitrum ABInventors: Björn Nilsson, Per-Åke Nygren, Mathias Uhlén
-
Patent number: 6503514Abstract: Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.Type: GrantFiled: July 7, 2000Date of Patent: January 7, 2003Assignee: Aventis Pasteur LimitedInventors: Bruno Flesselles, Michel H. Klein
-
Patent number: 6492492Abstract: Circularly permuted proteins are described wherein the natural termini of the polypeptide are joined and the resulting circular protein is opened at another point to create new C- and N- termini. The resulting protein exhibits some altered characteristic such as reduced substrate binding, for example. Fusion proteins can be made from the circularly permuted protein by attaching the second polypeptide to these newly created termini. These fusion proteins will have altered properties from a fusion protein made by attaching the second polypeptide to the natural termini. For example, the second peptide or protein can be attached at a position where it is more accessible to its substrate or intended target. In the preferred embodiment, the base circularly permuted biotin binding protein. In one embodiment, a flexible polypeptide loop important for the binding of biotin was opened by creation of the circularly permuted protein. The original termini (residues 13 and 139 of SEQ ID NO:1) were joined by a linker.Type: GrantFiled: April 2, 1999Date of Patent: December 10, 2002Assignee: University of WashingtonInventor: Patrick S. Stayton
-
Patent number: 6482924Abstract: Four antigenic preparations are provided, each of which contains a different protein from Leptospira which can be used immunologically in vaccines for leptospirosis caused by this organism. Also provided in the invention are polynucleotides encoding these four proteins and antibodies which bind the proteins for use in the diagnosis of leptospirosis.Type: GrantFiled: December 15, 1999Date of Patent: November 19, 2002Assignees: Pfizer Inc., Pfizer Products, Inc.Inventors: Eric A. Utt, Michael Stephen Willy, Don A. Dearwester
-
Patent number: 6471966Abstract: Fimbriae adhesins have a molecular weight of 2×105 and 2×107 Da, and are comprised of 90-95% protein and 1-3% sugar. Type 1 fimbriae include five different protein fractions of 14-20 kDa, most of which are associated with carbohydrates. Type P fimbriae also include five different protein fractions of 14-20 kDa, and one of the majority proteins is associated with carbohydrates. The process of the invention comprises: culturing E. coli strains CECT 4484 and CECT 4485; collecting the sediment by centrifugation and resuspending it in physiological saline followed by homogenization; centrifuging the homogenate and collecting the supernatant; precipitating the supernatant with saline, reconstituting the precipitate and dialyzing the solution; treating the dialyzate with sodium deoxycholate and, subjecting the product to two successive chromatographies with Sephacryl S-200 and Sepharose 4B. The product is used for treatment and prevention of infections of the urinary tract caused by fimbriated E. coli.Type: GrantFiled: August 4, 1998Date of Patent: October 29, 2002Assignee: Industrial Farmaceutica y de Especialidades, S.A.Inventors: Ricardo Palacios Pelaez, Alberto Martinez Garate, Jorge Martinez Quesada
-
Patent number: 6468523Abstract: Disclosed is a novel Lepidopteran- and Coleopteran-active &dgr;-endotoxin polypeptide, and compositions comprising the polypeptide, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that comprise nucleic acid segments encoding the polypeptide. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising the novel sequences of the invention, as well as methods for controlling an insect population, such as the Western Corn Rootworm and Colorado potato beetle, and for conferring to a plant population resistance to the target insect species.Type: GrantFiled: November 2, 1998Date of Patent: October 22, 2002Assignee: Monsanto Technology LLCInventors: Anne-Marie Light Mettus, James A. Baum
-
Patent number: 6464985Abstract: An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.Type: GrantFiled: August 30, 2000Date of Patent: October 15, 2002Assignee: Gundersen Lutheran Medical Foundation, Inc.Inventors: Steven M. Callister, Steven D. Lovrich, Ronald F. Schell, Dean A. Jobe
-
Patent number: 6461617Abstract: A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: February 23, 1999Date of Patent: October 8, 2002Assignees: Microbiological Research Authority, The Speywood Laboratory LimitedInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster